Please login to the form below

Not currently logged in
Email:
Password:

FDA approval for OTC delayed release omeprazole in US

The FDA grants final approval to Perrigo and its partner Dexcel Pharma Technologies to sell 20 mg omeprazole delayed-release tablets in the US

Over-the-counter (OTC) drug manufacturer and marketer Perrigo has said that the FDA has granted final approval to its partner Dexcel Pharma Technologies to sell 20 mg omeprazole delayed-release tablets in the US.

As the exclusive marketer and distributor of this product for the store brand OTC market in the US, Perrigo expects to begin shipping its product during Q1 2008. The company says its full year annual sales could be in the region of USD 150m to USD 200m.

Omeprazole is the active ingredient in UK-headquartered AstraZeneca's now off-patent antacid blockbuster Prilosec. Prilosec OTC is indicated for the treatment of frequent heartburn and had estimated current annual sales of approximately USD 750m in all US outlets, says Perrigo.

Based on pre-launch estimates, Perrigo's Omeprazole product is expected to contribute between USD 0.20 and USD 0.25 earnings per share in FY08. As a result of the Omeprazole launch, FY08 earnings are expected to be in the range of USD 1.32 to USD 1.47 per share.

Omeprazole is also sold OTC in a non-delayed release form by Proctor & Gamble.

11th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...